MeSH term
Frequency | Condition_Probility | Adult | 23 | 0.0 |
Aged | 10 | 0.0 |
Dihydropteroate Synthase/*genetics | 34 | 94.0 |
Female | 24 | 0.0 |
Humans | 66 | 0.0 |
Male | 25 | 0.0 |
Middle Aged | 22 | 0.0 |
Pneumocystis/enzymology/*genetics | 2 | 66.0 |
Animals | 36 | 0.0 |
Antimalarials/pharmacology | 3 | 16.0 |
DNA Primers/chemistry | 3 | 0.0 |
DNA, Protozoan/chemistry | 5 | 50.0 |
Drug Resistance/genetics | 9 | 5.0 |
Genotype | 15 | 0.0 |
Mutation | 8 | 0.0 |
Plasmodium falciparum/drug effects/*enzymology/genetics | 2 | 40.0 |
Polymorphism, Genetic | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 47 | 0.0 |
Tetrahydrofolate Dehydrogenase/*genetics | 17 | 13.0 |
Antimalarials/*therapeutic use | 7 | 23.0 |
Child | 17 | 0.0 |
Child, Preschool | 15 | 0.0 |
Drug Combinations | 12 | 2.0 |
Infant | 17 | 0.0 |
Malaria, Falciparum/*drug therapy | 5 | 41.0 |
*Mutation | 13 | 0.0 |
Prospective Studies | 4 | 0.0 |
Pyrimethamine/*therapeutic use | 5 | 35.0 |
Research Support, U.S. Gov't, P.H.S. | 16 | 0.0 |
Sulfadoxine/*therapeutic use | 5 | 50.0 |
Treatment Failure | 6 | 2.0 |
Drug Resistance, Bacterial/*genetics | 2 | 18.0 |
Sulfones/therapeutic use | 2 | 66.0 |
Comparative Study | 5 | 0.0 |
Mice | 4 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Pneumocystis Infections/*microbiology | 4 | 100.0 |
Rats | 4 | 0.0 |
Adolescent | 9 | 0.0 |
Drug Resistance | 5 | 0.0 |
Plasmodium falciparum/drug effects/enzymology/*genetics | 3 | 33.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Prevalence | 6 | 0.0 |
AIDS-Related Opportunistic Infections/drug therapy/*genetics/mortality | 2 | 100.0 |
Anti-Infective Agents/therapeutic use | 4 | 10.0 |
Dapsone/therapeutic use | 2 | 18.0 |
Drug Resistance, Microbial | 5 | 3.0 |
HIV-1 | 2 | 1.0 |
Pneumocystis/drug effects/*enzymology/genetics | 2 | 100.0 |
Pneumonia, Pneumocystis/drug therapy/*genetics/mortality | 2 | 100.0 |
Prognosis | 3 | 0.0 |
Survival Analysis | 2 | 0.0 |
Trimethoprim-Sulfamethoxazole Combination/therapeutic use | 3 | 8.0 |
Dihydropteroate Synthase/genetics | 4 | 50.0 |
Lung/microbiology | 3 | 17.0 |
Monkey Diseases/*microbiology | 2 | 66.0 |
Pneumonia, Pneumocystis/microbiology/*veterinary | 2 | 100.0 |
RNA, Ribosomal/genetics | 2 | 14.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Variation (Genetics) | 5 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
DNA, Protozoan/genetics | 3 | 18.0 |
Dihydropteroate Synthase/chemistry/*genetics | 2 | 100.0 |
Drug Resistance, Multiple/genetics | 2 | 4.0 |
Plasmodium falciparum/enzymology/*genetics | 2 | 25.0 |
Point Mutation | 6 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Tetrahydrofolate Dehydrogenase/chemistry/*genetics | 2 | 25.0 |
Dapsone/*pharmacology | 3 | 30.0 |
Leprostatic Agents/*pharmacology | 2 | 100.0 |
Microbial Sensitivity Tests | 5 | 2.0 |
Aged, 80 and over | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
DNA, Bacterial/analysis | 4 | 7.0 |
Drug Resistance, Microbial/genetics | 8 | 8.0 |
Serine/genetics | 2 | 2.0 |
Sulfonamides/*pharmacology | 4 | 9.0 |
Washington | 2 | 15.0 |
Alleles | 9 | 0.0 |
Pneumocystis/drug effects/enzymology/*genetics | 2 | 66.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Chloroquine/pharmacology | 2 | 2.0 |
Malaria, Falciparum/*epidemiology/parasitology | 2 | 66.0 |
*Point Mutation | 8 | 0.0 |
Thailand/epidemiology | 2 | 3.0 |
Analysis of Variance | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/microbiology | 5 | 29.0 |
Dihydropteroate Synthase/*genetics/metabolism | 8 | 100.0 |
Genes, Fungal | 3 | 2.0 |
Japan | 2 | 0.0 |
Pneumonia, Pneumocystis/drug therapy/*microbiology | 3 | 75.0 |
Dapsone/*therapeutic use | 2 | 40.0 |
Pneumocystis/*genetics | 3 | 42.0 |
Trimethoprim-Sulfamethoxazole Combination/*therapeutic use | 2 | 13.0 |
Amino Acid Substitution | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Antimalarials/*pharmacology | 7 | 25.0 |
Kenya | 3 | 6.0 |
Malaria, Falciparum/*parasitology | 2 | 14.0 |
Pyrimethamine/*pharmacology | 4 | 25.0 |
Sulfadoxine/*pharmacology | 4 | 57.0 |
Kinetics | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Dapsone/pharmacology/*therapeutic use | 2 | 100.0 |
Sequence Alignment | 3 | 0.0 |
Trimethoprim-Sulfamethoxazole Combination/pharmacology/*therapeutic use | 2 | 100.0 |
Pneumocystis/drug effects/*enzymology | 2 | 66.0 |
Recurrence | 2 | 0.0 |
Pneumocystis jiroveci/*genetics | 2 | 100.0 |
Malaria, Falciparum/drug therapy/parasitology | 2 | 40.0 |
Plasmodium falciparum/*drug effects/enzymology/genetics | 3 | 37.0 |
Uganda | 2 | 7.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Pyrimethamine/pharmacology | 5 | 41.0 |
Sulfadoxine/pharmacology | 2 | 66.0 |
Blood/parasitology | 2 | 50.0 |
DNA Restriction Enzymes/chemistry | 3 | 50.0 |
Plasmodium falciparum/drug effects/*genetics | 2 | 25.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Tetrahydrofolate Dehydrogenase/genetics | 3 | 3.0 |
Treatment Outcome | 2 | 0.0 |
DNA Primers | 4 | 0.0 |
Folic Acid Antagonists/*pharmacology | 3 | 6.0 |
Malaria, Falciparum/parasitology | 2 | 22.0 |
Vietnam | 2 | 10.0 |
Pneumonia, Pneumocystis/*microbiology | 2 | 50.0 |
Retrospective Studies | 3 | 0.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Triazines/pharmacology | 3 | 25.0 |
*Drug Resistance | 3 | 6.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Tanzania | 2 | 6.0 |
Sulfonamides/*pharmacology/therapeutic use | 2 | 100.0 |
Epidemiology, Molecular | 2 | 2.0 |
DNA, Fungal/analysis | 2 | 10.0 |
Plasmodium falciparum/*drug effects/enzymology/*genetics | 3 | 100.0 |
Sulfones/*pharmacology | 2 | 20.0 |
Africa | 2 | 2.0 |
Malaria, Falciparum/drug therapy | 3 | 60.0 |
Pyrimethamine/therapeutic use | 3 | 23.0 |
Sulfadoxine/therapeutic use | 2 | 25.0 |
Mutation/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Folic Acid Antagonists/pharmacology | 3 | 16.0 |
India | 2 | 0.0 |
Plasmids | 2 | 0.0 |
AIDS-Related Opportunistic Infections/*microbiology | 2 | 11.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Gene Expression | 2 | 0.0 |
HIV Infections/complications | 2 | 4.0 |
Trimethoprim-Sulfamethoxazole Combination/pharmacology | 3 | 42.0 |
Portugal | 2 | 3.0 |
Reproducibility of Results | 2 | 0.0 |
Drug Resistance, Fungal/*genetics | 4 | 50.0 |
